CSPC Pharmaceutical Group Limited
(Incorporated in Hong Kong with limited liability)

Announcements & Notices       

2018-December-21	CONTINUING CONNECTED TRANSACTIONS - LEASE AGREEMENTS (in PDF)
2018-December-17	VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSING AND COMMERCIALIZATION AGREEMENT (in PDF)
2018-December-11	PROGRESS UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF CSPC XNW GROUP ON THE SHENZHEN STOCK EXCHANGE (in PDF)
2018-November-26	VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "AMOXICILLIN CAPSULES" (in PDF)
2018-November-26	VOLUNTARY ANNOUNCEMENT - THE GROUP'S "TIROFIBAN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION" WAS GRANTED DRUG REGISTRATION APPROVAL (in PDF)
2018-November-26	VOLUNTARY ANNOUNCEMENT - THE GROUP'S PRODUCT CANDIDATE "ALMB-0166" WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA (in PDF)
2018-November-19	UNAUDITED RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2018 (in PDF)
2018-November-7	DATE OF BOARD MEETING (in PDF)
2018-November-1	CONTINUING CONNECTED TRANSACTION - RENEWAL OF MASTER SALES AGREEMENT (in PDF)
2018-October-8	VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSE AND COMMERCIALIZATION AGREEMENT (in PDF)
2018-September-26	VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSE AND COLLABORATION AGREEMENT (in PDF)
2018-August-30	LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
2018-August-30	RESIGNATION OF DIRECTOR (in PDF)
2018-August-20	LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
2018-August-20	APPOINTMENT OF EXECUTIVE DIRECTOR AND NON-COMPLIANCE WITH RULE 3.10A OF THE LISTING RULES (in PDF)
2018-August-20	ADOPTION OF RESTRICTED SHARE AWARD SCHEME (in PDF)
2018-August-20	2018 INTERIM RESULTS ANNOUNCEMENT (in PDF)
2018-August-8	DATE OF BOARD MEETING (in PDF)
2018-August-6	CONNECTED TRANSACTION - ACQUISITION OF 29.9% EQUITY INTEREST IN CSPC YUANDA (DALIAN) PHARMACEUTICAL CO., LTD. (in PDF)
2018-July-23	VOLUNTARY ANNOUNCEMENT - "STATE KEY LABORATORY FOR NOVEL PHARMACEUTICAL PREPARATIONS AND EXCIPIENTS" RATED AS EXCELLENT CLASS OF STATE KEY LABORATORY (in PDF)
2018-July-10	VOLUNTARY ANNOUNCEMENT - PRODUCT CO-DEVELOPMENT AND STRATEGIC COLLABORATION AGREEMENT (in PDF)
2018-July-10	VOLUNTARY ANNOUNCEMENT - THE GROUP'S INVESTIGATIONAL NEW DRUG "CSPCHA115" WAS GRANTED CLINICAL TRIAL APPROVAL BY THE U.S. FDA (in PDF)
2018-July-10	VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "CAPTOPRIL TABLETS" (in PDF)
2018-July-9	LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
2018-July-9	APPOINTMENT OF EXECUTIVE DIRECTOR (in PDF)
2018-June-4	VOLUNTARY ANNOUNCEMENT - ADMISSION OF THE GROUP'S "PACLITAXEL FOR INJECTION (ALBUMIN-BOUND)" TO THE "LIST OF MARKETED DRUGS OF CHINA" (in PDF)
2018-May-25	POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 25 MAY 2018 (in PDF)
2018-May-25	LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
2018-May-25	APPOINTMENT OF VICE-CHAIRMAN AND CHANGE OF ROTATING CHIEF EXECUTIVE OFFICER (in PDF)
2018-May-25	UNAUDITED RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2018 (in PDF)
2018-May-21	VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR "QIMAITE" (TRAMADOL HYDROCHLORIDE TABLETS) (in PDF)
2018-May-14	DATE OF BOARD MEETING (in PDF)
2018-May-10	VOLUNTARY ANNOUNCEMENT - "Q101-PEGYLATED RECOMBINANT HUMAN INTERFERON-alpha2a FOR INJECTION" FOR THE TREATMENT OF HEPATITIS WAS GRANTED CLINICAL TRIAL APPROVAL (in PDF)
2018-May-10	VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "DOXOFYLLINE GLUCOSE FOR INJECTION" AND "DOXOFYLLINE SODIUM CHLORIDE FOR INJECTION" (in PDF)
2018-April-20	NOTICE OF ANNUAL GENERAL MEETING (in PDF)
2018-April-18	VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSING AGREEMENT (in PDF)
2018-April-16	VOLUNTARY ANNOUNCEMENT - "VINORELBINE TARTRATE LIPOSOME INJECTION" FOR THE TREATMENT OF LUNG CANCER WAS GRANTED CLINICAL TRIAL APPROVAL (in PDF)
2018-April-12	VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR"WEIHONG"(AZITHROMYCIN TABLETS) (in PDF)
2018-March-19	ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2017 (in PDF)
2018-March-16	VOLUNTARY ANNOUNCEMENT - "RECOMBINANT ANTI-EpCAM AND ANTI-CD3 HUMAN-MOUSE CHIMERIC BISPECIFIC ANTIBODY FOR INJECTION" WAS GRANTED DRUG CLINICAL TRIAL APPROVAL (in PDF)
2018-March-11	VOLUNTARY ANNOUNCEMENT - THE GROUP'S DRUG "BUTYLPHTHALIDE" WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA (in PDF)
2018-March-7	DATE OF BOARD MEETING (in PDF)
2018-February-12	VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "PACLITAXEL FOR INJECTION (ALBUMIN-BOUND)" (in PDF)
2018-February-6	VOLUNTARY ANNOUNCEMENT-THE GROUP'S GASTRIC CANCER DRUG "DP303c" WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA (in PDF)
2018-January-9	VOLUNTARY ANNOUNCEMENT - ACQUISITION OF 39.56% EQUITY INTEREST IN WUHAN YZY BIOPHARMA CO., LTD. (in PDF)
2024	2024 Announcements & Notices
2023	2023 Announcements & Notices
2022	2022 Announcements & Notices
2021	2021 Announcements & Notices
2020	2020 Announcements & Notices
2019	2019 Announcements & Notices
2017	2017 Announcements & Notices
2016	2016 Announcements & Notices
2015	2015 Announcements & Notices
2014	2014 Announcements & Notices
2013	2013 Announcements & Notices
2012	2012 Announcements & Notices
2011	2011 Announcements & Notices
2010	2010 Announcements & Notices
2009	2009 Announcements & Notices
2008	2008 Announcements & Notices
2007	2007 Announcements & Notices
2006	2006 Announcements & Notices